Systematic review of 11 studies of neoadjuvant immune checkpoint inhibition for resectable mucosal head and neck SCC (368 patients meta-analysed): partial (HR 0.53) and major (HR 0.34) pathologic response were associated with better DFS up to 2 years, but not with OS.
Meta-analysisn = 368
Mastrolonardo et al. Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-Analysis